Unlocking the health benefits of cannabinoids.

Berlin, April 1, 2026 – On the second anniversary of the German Cannabis Act (CanG) coming into effect, the second interim report on the Evaluation of the Recreational Cannabis Act (EKOCAN) was published today. From Sanity Group’s perspective, this marks another important milestone toward an evidence-based cannabis policy in Germany: The data now available will help to assess the effects of this new regulation in a nuanced manner and to further develop the existing legal framework on a scientific basis. “The Cannabis Act was an important and long-overdue paradigm shift,” explains Finn Hänsel, founder and CEO of Sanity Group. “Two years later, it is clearer how important it is to develop regulations not ideologically but based on data.”

Sanity Group, one of Germany’s leading cannabis companies, is delighted to announce a partnership with Curaleaf Laboratories, one of the UK-leading pharmaceutical-grade medical cannabis manufacturers. The partnership brings together Sanity Group’s international expertise in cannabinoid-based therapeutics with Curaleaf Laboratories’ established manufacturing, quality, and commercial capabilities. Together, the companies will collaborate to develop, manufacture, and commercialize innovative medical cannabis products tailored to the needs of UK patients and healthcare professionals.

• Germany’s leading medical cannabis company, Sanity Group has entered strategic agreement with longtime investor and partner, Organigram Global Inc.
• Transaction valuation: Sanity Group has been valued at a total of up to EUR 250 million, consisting of an upfront EUR 130 million and up to EUR 120 million linked to defined performance metrics for twelve months ending March 31, 2027
• This catalyzes Sanity Group’s long term international growth and international expansion across the European cannabis market

As one of Germany’s leading companies in the medical cannabis sector, Sanity Group has entered into an agreement on a strategic transaction with its long-standing investor and production partner, Organigram Global Inc. (“Organigram”). Based on two highly complementary business models, the two companies are pursuing an integrated approach that prioritizes global growth, diversification of the product portfolio, and, in turn, a sustainable improvement in the supply of cannabis patients. The publicly listed Toronto-headquartered company Organigram [1] contributes extensive expertise in quality-assured cultivation, processing and innovative cannabis product development to the partnership—complementing Sanity Group’s capabilities and experience to create a strong foundation for long-term growth and international expansion across the European cannabis market. Sanity Group will continue to focus on the pharmaceutical segment, confirms founder and CEO Finn Hänsel: “Building on our complementary strengths and synergies, we and Organigram plan not only to sustainably secure the supply of cannabis for patients in Europe, but to strengthen it over the long term. Our focus on distributing medical cannabis to pharmacies, as well as on scientific research and innovation, therefore remains unchanged.”